• 1
    Norris AM, Laing EJ, Valli VE, et al. Canine bladder and urethral tumors: A retrospective study of 115 cases (1980–1985). J Vet Intern Med 1992;6:145153.
  • 2
    Withrow SJ. Tumors of the urinary system. In: WithrowSJ, MacEwenEG, eds. Small Animal Clinical Oncology, 3rd ed. Philadelphia , PA : WB Saunders; 2001.
  • 3
    Priester WA, McKay FW. The Occurrence of Tumors in Domestic Animals. Monograph 54. Bethesda , MD : National Cancer Institute; 1986.
  • 4
    Knapp DW, Glickman NW, DeNicola DB, et al. Naturally occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer. Urol Oncol 2000; 5: 4749.
  • 5
    Priester WA, McKay FW. The occurrence of tumors in domestic animals. Monogr Natl Cancer Inst 1980;54:110.
  • 6
    Glickman LT, Schofer FS, McKee LJ. Epidemiology study of insecticide exposures, obesity, and risk of bladder cancer in household dogs. J Toxicol Environ Health 1989;28:407414.
  • 7
    Weller RE, Wold AM, Dyjido A. Transitional cell carcinoma of the bladder associated with cyclophosphamide therapy in a dog. J Am Anim Hosp Assoc 1979;5:733736.
  • 8
    Macy DW, Withrow SJ, Hoopes J. Transitional cell carcinoma of the bladder associated with cyclophosphamide administration. J Am Anim Hosp Assoc 1983;19:965969.
  • 9
    Hayes HM Jr, Hoover R., Tarone R. Bladder cancer in pet dogs: A sentinel for environmental cancer J Epidemiol 1981;114:229233.
  • 10
    IARC. Overall evaluations of carcinogenicity: An updating of IARC monographs vols 1 to 42. IARC Monogr Eval Carcinog Risks Hum (Suppl) 1987;7:1440.
  • 11
    Hartage P., Silverman D., Hoover R., et al. Changing cigarette habits and bladder cancer risk: A case-control study. J Natl Cancer Inst 1987;78:11191125.
  • 12
    Levine LA, Richie JP. Urologic complications of cyclophos-phamide. J Urol 1989;141:10631069.
  • 13
    Mostofi K., Ito N., Weinstein R. Pathology; the need for standardization of pathological examination and reporting. In: DenisL., et al, eds. Developments in Bladder Cancer. New York , NY : Alan R Liss Inc; 1986: 6783.
  • 14
    Valli VE, Norris A., Jacobs RM, et al. Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival. J Comp Pathol 1995;113:113130.
  • 15
    Clemo FAS, DeNicola DB, Carlton WW, et al. Immunoreactiv-ity of canine transitional cell carcinoma of the urinary bladder with monoclonal antibodies to tumor-associated glycoprotein 72. Vet Pathol 1995;32:155161.
  • 16
    Clemo FAS, DeNicola DB, Delaney LJ. Immunohistochemical evaluation of canine carcinomas with monoclonal antibody B72.3. Vet Pathol 1993; 30: 140145.
  • 17
    Molinolo A., Simpson JF, Thor A., Schlom J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 1990; 50: 12911298.
  • 18
    Gamblin RM, Sagartz JE, Couto CG. Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. Am J Vet Res 1997;58:857863.
  • 19
    Chodak GW, Hospelhorn V., Judge SM, et al. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 1988;48:20832088.
  • 20
    Nguyen M., Watanabe H., Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356361.
  • 21
    Allen DK, Waters DJ, Knapp DW, Kuczek T. High urine con-Canine Transitional Cell Carcinoma. 143. centrations of basic fibroblast growth factor in dogs with bladder cancer. J Vet Intern Med 1996; 10: 231234.
  • 22
    Campbell SC, Volpert OV, Ivanovich M., Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998;58:12981304.
  • 23
    Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273278.
  • 24
    Shibata MA, Hasegawa R., Shirai T., et al. Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogen-esis model. Int J Cancer 1993;55:10111017.
  • 25
    Cohen SM, Zenser TV, Murasaki G., et al. Aspirin inhibition of N-[4-(5-nitro-2furyl)-2-thiazolyl] formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase. Cancer Res 1981;41:33553359.
  • 26
    Rao KV, Detrisac CJ, Steele VE, et al. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996;17:14351438.
  • 27
    Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-n-(4 hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60:55995602.
  • 28
    Khan KNM, Knapp DW, DeNicola DB, Harris K. Expression of cox-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61:478481.
  • 29
    Mohammed SI, Knapp DW, Bostwick DG, Foster RS, et al. Expression of cyclooxygenase-2 (cox-2) in human invasive transitional cell carcinoma of the urinary bladder. Cancer Res 1999;59:56475650.
  • 30
    Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:55755589.
  • 31
    Mohammed SI, Coffman K., Glickman NW, et al. Prostaglandin E2 concentrations in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2001;64:14.
  • 32
    Borjesson DL, Christopher MM, Ling GV. Detection of canine transitional cell carcinoma using a bladder tumor antigen urine dipstick test. Vet Clin Pathol 1999;28:3338.
  • 33
    Billet JPHG, Moore AH, Holt PE. Evaluation of a bladder tumor antigen test for the diagnosis of lower urinary tract malignancies in dogs. Am J Vet Res 2002;63:370373.
  • 34
    Knapp DW. Medical therapy of canine transitional cell carcinoma of the urinary bladder. In: BonaguraJD, ed. Kirk's Current Veterinary Therapy XII. Philadelphia , PA : WB Saunders; 1995: 10161018.
  • 35
    Anderson WI, Dunham BM, King JM, et al. Presumptive subcutaneous transplantation of a urinary bladder transitional cell carcinoma of the urinary bladder in a dog. Cornell Vet 1989;79:263266.
  • 36
    Chun R., Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279283.
  • 37
    Leveille R., Biller DS, Partington BP, Miyabayashi T. Sono-graphic investigation of transitional cell carcinoma of the urinary bladder in small animals. Vet Radiol Ultrasound 1992;33:103107.
  • 38
    DeGortari AE, Widmer WR, Han CM, Knapp DW. Imaging of canine urinary bladder tumors. Proceedings of the 19th Veterinary Cancer Society Conference, Wood's Hole, MA, 1999: 83.
  • 39
    Owen LN. TNM Classification of Tumours in Domestic Animals, 1st ed. Geneva : World Health Organization; 1980: 34.
  • 40
    Fries CL, Binnington AG, Valli VE, et al. Enterocystoplasty with cystectomy and subtotal intracapsular prostatectomy in the male dog. Vet Surg 1991;20:104112.
  • 41
    Stone EA, George TF, Gilson SD, Page RL. Partial cystectomy for urinary bladder neoplasia: Surgical technique and outcome in 11 dogs. J Small Anim Pract 1996;37:480485.
  • 42
    Stone EA, Withrow SJ, Page RL, et al. Ureterocolonic anastomosis in ten dogs with transitional cell carcinoma. Vet Surg 1988;17:147153.
  • 43
    White RN, Davies JV, Gregory SP. Vaginourethroplasty for treatment of urethral obstruction in the bitch. Vet Surg 1996;25:503510.
  • 44
    Schwartz PD, Egger EL, Klause SE. Modified “cup-patch” il-eocystoplasty for urinary bladder reconstruction in a dog. J Am Vet Med Assoc 1991;198:273277.
  • 45
    Smith JD, Stone EA, Gilson SD. Placement of a permanent cystostomy catheter to relieve urine outflow obstruction in dogs with transitional cell carcinoma. J Am Vet Med Assoc 1995;206:496499.
  • 46
    Lengerich EJ, Teclaw RF, Mendlein M., et al. Pet populations in the catchment area of the Purdue Comparative Oncology Program. J Am Vet Med Assoc 1992;200:5156.
  • 47
    Helfand SC, Hamilton TA, Hungerford LL, et al. Comparison of three treatments for transitional cell carcinoma of the bladder in the dog. J Am Anim Hosp Assoc 1994;30:270275.
  • 48
    Herr HW, Shipley WU, Bajorin DF. Cancer of the bladder. In: DeVitaVT, HellmanS., RosenbergSA, eds. Principles and Practice of Oncology, 6th ed. Philadelphia , PA : Lippincott-Raven Publishers; 2001: 13961418.
  • 49
    Walker M., Breider M. Intraoperative radiotherapy of canine bladder cancer. Vet Radiol 1987;28:200204.
  • 50
    McCaw DL, Lattimer JC. Radiation and cisplatin for treatment of canine urinary bladder carcinoma, a report of 2 case histories. Vet Radiol 1988;29:264268.
  • 51
    Poirier VJ, Vail DM, Forrest LJ. Pilot study evaluating palliative radiotherapy (RT) in combination with mitoxantrone/piroxicam in the treatment of transitional cell carcinoma (10 cases). Proceedings of the 19th Veterinary Cancer Society Conference, Wood's Hole, MA, 1999: 18.
  • 52
    Rocha, TA, Mauldin GN, Patnaik AK, Bergman PJ. Prognostic factors in dogs with urinary bladder carcinoma. J Vet Intern Med 2000; 14:486490.
  • 53
    Song D., Wientjes MG, Au JLS. Bladder tissue pharmacokinet-ics of intravesicular taxol. Cancer Chemother Pharmacol 1997;40:285292.
  • 54
    Cozzi PJ, Bajorin DG, Tong W., et al. Toxicology and phar-macokinetics of intravesicular gemcitabine: A preclinical study in dogs. Clin Cancer Res 1999;5:26292637.
  • 55
    Song D., Wientjes MG, Gan Y. Bladder tissue pharmacokinetics and antitumor effect of intravesicular 5-fluorouridine. Clin Cancer Res 1997;3:901909.
  • 56
    Lucroy MD, Peavy GM, Healey TA, et al. Endogenous pho-tosensitization for photodynamic therapy of canine transitional cell carcinoma: Preclinical evaluation. Proceedings of the 21st Veterinary Cancer Society Conference, Baton Rouge, LA, 2001: 54.
  • 57
    Knapp DW, Richardson RC, Bottoms GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214218.
  • 58
    Husdon MA, Herr HW. Carcinoma in situ of the bladder. J Urol 1995;153:564572.
  • 59
    Knapp DW, Chan TCK, Kuczek T., et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56:801805.
  • 60
    Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cy-clooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive bladder cancer. Cancer Res 2002;62:356358.
  • 61
    Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221226.
  • 62
    Knapp DW, Schmidt BR, Widmer WR, et al. Preliminary results of carboplatin/piroxicam therapy in canine transitional cell carcinoma. Proceedings 17th Veterinary Cancer Society–American College of Veterinary Radiology Conference, Chicago, IL, 1997: 89.
  • 63
    Ostrander EA, Giniger E. Insights from model systems. Semper. Mutsaers, Widmer, and Knapp. fidelis: What man's best friend can teach us about human biology and disease. Am J Hum Genet 1997; 61: 475480.
  • 64
    Uddhav K., Ketan S. Advances in the human genome project. A review. Mol Biol Rep 1998; 25: 2743.
  • 65
    de Larco JE, Wuertz BRK, Manivel JC, Furcht LT. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 2001;61:28572861.
  • 66
    Chun R., Knapp DW, Widmer WR, et al. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983–1993). J Am Vet Med Assoc 1996;209:15881591.
  • 67
    Moore AS, Cardona A., Shapiro W., Madewell BR. Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra. A retrospective study of 15 dogs. J Vet Intern Med 1990; 4: 148152.
  • 68
    Shapiro W., Kitchell BE, Fossum TN, et al. Cisplatin for the treatment of transitional cell carcinoma and squamous cell carcinomas in dogs. J Am Vet Med Assoc 1988;193:15301533.
  • 69
    Ogilvie GK, Obradovich JE, Elmslie RE, et al. Efficacy of mi-toxantrone against various neoplasms in dogs. J Am Vet Med Assoc 1991;198:16181621.
  • 70
    Ogilvie GK, Reynolds HA, Richardson RC, et al. Phase II evaluation of doxorubicin treatment of various canine neoplasms. J Am Vet Med Assoc 1989;195:15801583.
  • 71
    Hammer AS, Couto CG, Ayl RD, Shank KA. Treatment of tumor-bearing dogs with actinomycin D. J Vet Intern Med 1994;8:236239.
  • 72
    Hankes BF, Silverman DE. SEER Cancer Statistics Review, 1973–1973. Bethesda , MD : National Cancer Institute; 1993.
  • 73
    Patronek GJ, Waters DJ, Glickman LT. Comparative longevity of pet dogs and humans: Implications for gerontology research. J Ger-entol A Biol Sci Med Sci 1997;52:B171B178.
  • 74
    Cummings KB. Uroepithelial tumors. In: MoossaAR, RobsonMC, SchimpffSC, eds. Comprehensive Textbook of Oncology. Baltimore , MD : Williams and Wilkins; 1991: 10671087.
  • 75
    Blomjous CEM, Schipper NW, Baak JPA, et al. Retrospective study of prognostic importance of DNA flow cytometry on urinary bladder carcinoma. J Clin Pathol 1988;41:2125.
  • 76
    Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:12591264.
  • 77
    Esrig D., Spruck CH, Nichols PW, et al. P53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:13891397.
  • 78
    Whitmore WF. Management of invasive bladder neoplasms. Semin Urol 1983;1:3441.
  • 79
    Wood DP Jr, Montie JE, Pontes JE, Levin HS. Identification of transitional cell carcinoma of the prostate in bladder cancer patients: A prospective study. J Urol 1989;142:8385.
  • 80
    Stephenson WT, Holmes FF, Noble MJ, Gerald KB. Analysis of bladder carcinoma by subsite. Cystoscopic location may have prognostic value. Cancer 1990; 66: 16301635.